

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Beigelman Leonid</u> (Last) (First) (Middle) C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR (Street) SOUTH SAN FRANCISCO CA 94080 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/15/2020	3. Issuer Name and Ticker or Trading Symbol <u>Aligos Therapeutics, Inc. [ALGS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p align="center">President</p>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,026,991 ⁽¹⁾	D	
Common Stock	69,744 ⁽¹⁾	I	Trust ⁽²⁾
Common Stock	69,744 ⁽¹⁾	I	Trust ⁽³⁾
Common Stock	35,408 ⁽¹⁾	I	Trust ⁽⁴⁾
Common Stock	35,408 ⁽¹⁾	I	Trust ⁽⁵⁾

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(6)	02/19/2030	Common Stock	65,849 ⁽¹⁾	3.45 ⁽¹⁾	D	
Stock Option (Right to Buy)	(6)	02/19/2030	Common Stock	202,399 ⁽¹⁾	3.45 ⁽¹⁾	D	
Series A Preferred Stock	(7)	(7)	Common Stock	163,842 ⁽¹⁾⁽⁷⁾	(7)	I	Trust ⁽⁸⁾
Series A Preferred Stock	(7)	(7)	Common Stock	13,559 ⁽¹⁾⁽⁷⁾	(7)	I	Trust ⁽⁹⁾
Series A Preferred Stock	(7)	(7)	Common Stock	13,559 ⁽¹⁾⁽⁷⁾	(7)	I	Trust ⁽¹⁰⁾
Series B-1 Preferred Stock	(7)	(7)	Common Stock	50,781 ⁽¹⁾⁽⁷⁾	(7)	I	Trust ⁽⁸⁾
Series B-1 Preferred Stock	(7)	(7)	Common Stock	3,359 ⁽¹⁾⁽⁷⁾	(7)	I	Trust ⁽⁹⁾
Series B-1 Preferred Stock	(7)	(7)	Common Stock	3,359 ⁽¹⁾⁽⁷⁾	(7)	I	Trust ⁽¹⁰⁾
Series B-2 Preferred Stock	(7)	(7)	Common Stock	21,724 ⁽¹⁾⁽⁷⁾	(7)	I	Trust ⁽⁸⁾
Series B-2 Preferred Stock	(7)	(7)	Common Stock	1,437 ⁽¹⁾⁽⁷⁾	(7)	I	Trust ⁽⁹⁾
Series B-2 Preferred Stock	(7)	(7)	Common Stock	1,437 ⁽¹⁾⁽⁷⁾	(7)	I	Trust ⁽¹⁰⁾

Explanation of Responses:

1. Reflects a 1-for-9.3197 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

2. Leonid Beigelman and Natalia Lozovsky, Trustees, or their successors in trust, under the Beigelman 2020 Grantor Retained Annuity Trust dated June 25, 2020.
3. Natalia Lozovsky and Leonid Beigelman, Trustees, or their successors in trust, under the Lozovsky 2020 Grantor Retained Annuity Trust dated June 25, 2020.
4. Leonid Beigelman and Natalia Lozovsky, Trustees, or their successors in trust, under the Dina Beigelman 2020 Irrevocable Trust, dated July 02, 2020.
5. Leonid Beigelman and Natalia Lozovsky, Trustees, or their successors in trust, under the Victor Beigelman 2020 Irrevocable Trust, dated July 02, 2020.
6. The shares subject to the option are early exercisable. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from December 23, 2019 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
7. At any time at the holder's election or automatically upon the closing of the Issuer's initial public offering, shares of the Issuer's preferred stock will convert into shares of the Issuer's common stock on a one for one basis without payment or consideration. The preferred stock has no expiration date.
8. Beigelman and Lozovsky Living Trust.
9. Dina Beigelman Irrevocable Trust.
10. Victor Beigelman Irrevocable Trust.

/s/ Lucinda Y. Quan, as
attorney-in fact for Leonid 10/15/2020
Beigelman

** Signature of Reporting Date
Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of (i) the Chief Executive Officer of Aligos Therapeutics, Inc., a Delaware corporation (the “**Company**”), who is currently Lawrence Blatt, (ii) the Company’s Chief Financial Officer, who is currently Lesley Ann Calhoun and (iii) the Company’s General Counsel, who is currently Lucinda Quan, and their respective successors, signing singly, with full power of substitution, as the undersigned’s true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of the Company, Forms 3, 4 and 5 (including amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations thereunder and a Form ID, Uniform Application for Access Codes to File on EDGAR;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4 or 5 or Form ID and timely file such forms (including amendments thereto) and application with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

The undersigned agrees that each such attorney-in-fact herein may rely entirely on information furnished orally or in writing by the undersigned to such attorney-in-fact. The undersigned also agrees to indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based upon any untrue statements or omission of necessary facts in the information provided by the undersigned to such attorney-in fact for purposes of executing, acknowledging, delivering or filing Forms 3, 4 or 5 (including amendments thereto) or Form ID and agrees to reimburse the Company and such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This Power of Attorney supersedes any power of attorney previously executed by the undersigned regarding the purposes outlined in the first paragraph hereof (“**Prior Powers of Attorney**”), and the authority of the attorneys-in-fact named in any Prior Powers of Attorney is hereby revoked.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier (a) revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (b) superseded by a new power of attorney regarding the purposes outlined in the first paragraph hereof dated as of a later date.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of September 2, 2020.

/s/ Leonid Beigelman
Leonid Beigelman